Log in

Cue Biopharma Stock Price, News & Analysis (NASDAQ:CUE)

$7.61
+0.31 (+4.25 %)
(As of 10/23/2019 01:37 AM ET)
Today's Range
$7.30
Now: $7.61
$7.78
50-Day Range
$7.12
MA: $8.11
$9.09
52-Week Range
$4.16
Now: $7.61
$9.94
Volume32,170 shs
Average Volume85,317 shs
Market Capitalization$171.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUE
CUSIPN/A
Phone617-949-2680

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.14 million
Book Value$1.64 per share

Profitability

Net Income$-38,980,000.00
Net Margins-2,039.41%

Miscellaneous

Employees46
Market Cap$171.86 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.


Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

How were Cue Biopharma's earnings last quarter?

Cue Biopharma Inc (NASDAQ:CUE) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.56) by $0.10. The company earned $1.06 million during the quarter. Cue Biopharma had a negative return on equity of 151.93% and a negative net margin of 2,039.41%. View Cue Biopharma's Earnings History.

When is Cue Biopharma's next earnings date?

Cue Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Cue Biopharma.

What price target have analysts set for CUE?

1 Wall Street analysts have issued 1-year price objectives for Cue Biopharma's shares. Their predictions range from $13.00 to $13.00. On average, they anticipate Cue Biopharma's stock price to reach $13.00 in the next year. This suggests a possible upside of 70.8% from the stock's current price. View Analyst Price Targets for Cue Biopharma.

What is the consensus analysts' recommendation for Cue Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cue Biopharma.

Has Cue Biopharma been receiving favorable news coverage?

News coverage about CUE stock has been trending somewhat negative on Wednesday, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cue Biopharma earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Cue Biopharma.

Are investors shorting Cue Biopharma?

Cue Biopharma saw a decrease in short interest in the month of September. As of September 15th, there was short interest totalling 1,140,000 shares, a decrease of 6.6% from the August 15th total of 1,220,000 shares. Based on an average daily trading volume, of 93,500 shares, the short-interest ratio is currently 12.2 days. Approximately 6.4% of the shares of the stock are sold short. View Cue Biopharma's Current Options Chain.

Who are some of Cue Biopharma's key competitors?

What other stocks do shareholders of Cue Biopharma own?

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the folowing people:
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 58)
  • Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 62)
  • Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 43)
  • Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 46)
  • Dr. Steven C. Almo, Co-Founder and Chairman of Scientific & Clinical Advisory Board (Age 58)

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.12%). Company insiders that own Cue Biopharma stock include Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri and Kerri-Ann Millar. View Institutional Ownership Trends for Cue Biopharma.

Which institutional investors are buying Cue Biopharma stock?

CUE stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Cue Biopharma stock in the last two years include Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri and Kerri-Ann Millar. View Insider Buying and Selling for Cue Biopharma.

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $7.61.

How big of a company is Cue Biopharma?

Cue Biopharma has a market capitalization of $171.86 million and generates $1.14 million in revenue each year. The company earns $-38,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cue Biopharma employs 46 workers across the globe.View Additional Information About Cue Biopharma.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is http://www.cuebiopharma.com/.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-949-2680 or via email at [email protected]


MarketBeat Community Rating for Cue Biopharma (NASDAQ CUE)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Cue Biopharma and other stocks. Vote "Outperform" if you believe CUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: What is Cost of Debt?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel